Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Emodepside Formulations
NCT06412926Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emodepside in onchocerciasis and soil-transmitted helminthiasis (STH) (2 arms), sponsored by Bayer. Primary endpoints: Maximum observed concentration and Area under the concentration vs. time curve. Started May 2024; status: completed.
02
Drugs
emodepside
03
Conditions
onchocerciasissoil-transmitted helminthiasis (STH)
Beyond the preview
Go deeper on NCT06412926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412926.